ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
6,040.04
1.10%
US Tech 100
21,198.40
1.36%
Dow Jones
43,297.03
0.91%
Brent Oil
73.285
0.00%
Bitcoin
98,483.45
-0.20%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Biogen Inc (BIIB)

  7. Biogen Inc (BIIB) News

BIIB

Biogen (BIIB)

Biogen Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BIIB
DateTimeSourceHeadlineSymbolCompany
12/09/20244:57PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
12/09/20244:56PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
12/09/202410:33AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BIIBBiogen Inc
12/04/20246:31PMPR Newswire (US)"LEQEMBI®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in MexicoNASDAQ:BIIBBiogen Inc
11/27/20247:31PMPR Newswire (US)"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South KoreaNASDAQ:BIIBBiogen Inc
11/19/20241:00AMGlobeNewswire Inc.Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease ActivityNASDAQ:BIIBBiogen Inc
11/14/20241:29PMPR Newswire (US)Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's DiseaseNASDAQ:BIIBBiogen Inc
11/14/202411:23AMGlobeNewswire Inc.Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s DiseaseNASDAQ:BIIBBiogen Inc
11/07/20244:23PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
11/04/20244:39PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
10/30/20247:30PMGlobeNewswire Inc.Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) ConferenceNASDAQ:BIIBBiogen Inc
10/30/20244:45PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BIIBBiogen Inc
10/30/20244:31PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BIIBBiogen Inc
10/30/20246:55AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BIIBBiogen Inc
10/30/20246:37AMIH Market NewsUS Futures Rise as Tech Earnings Drive Market Optimism; Oil Prices Edge UpNASDAQ:BIIBBiogen Inc
10/29/20246:00PMGlobeNewswire Inc.Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological DiseasesNASDAQ:BIIBBiogen Inc
10/29/20248:00AMGlobeNewswire Inc.Biogen Appoints Daniel Quirk, MD, as Chief Medical OfficerNASDAQ:BIIBBiogen Inc
10/28/20248:30AMGlobeNewswire Inc.Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025NASDAQ:BIIBBiogen Inc
10/26/20248:15PMGlobeNewswire Inc.Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024NASDAQ:BIIBBiogen Inc
10/24/20247:30AMGlobeNewswire Inc.Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual ConferenceNASDAQ:BIIBBiogen Inc
10/22/20247:30AMGlobeNewswire Inc.Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024NASDAQ:BIIBBiogen Inc
10/09/20247:30AMGlobeNewswire Inc.Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant RecipientsNASDAQ:BIIBBiogen Inc
10/08/20247:30AMGlobeNewswire Inc.New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMANASDAQ:BIIBBiogen Inc
10/07/20247:08PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
09/24/20241:00AMGlobeNewswire Inc.UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024NASDAQ:BIIBBiogen Inc
09/12/20247:31AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BIIBBiogen Inc
09/12/20247:30AMGlobeNewswire Inc.Biogen Board Appoints Two New Independent DirectorsNASDAQ:BIIBBiogen Inc
09/05/20246:00AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
09/04/20247:30AMGlobeNewswire Inc.Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMANASDAQ:BIIBBiogen Inc
09/03/20241:00PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BIIBBiogen Inc
 Showing the most relevant articles for your search:NASDAQ:BIIB

Your Recent History

USOTC
EEGI
ELine Entertainment (CE)
USOTC
HLLK
Hallmark Venture (PK)
AMEX
KULR
KULR Technology
USOTC
HIRU
Hiru (PK)
USOTC
NLST
Netlist (QB)
USOTC
VXIT
Virexit Technologies (PK)
USOTC
AABB
Asia Broadband (PK)
USOTC
PHIL
PHI (PK)
USOTC
RDGL
Vivos (QB)
USOTC
IGPK
Intergrated Cannabis Sol... (PK)
USOTC
SPZI
Spooz (PK)
USOTC
ZHUD
Zhuding (PK)
NASDAQ
TSLA
Tesla
USOTC
IFUS
Impact Fusion (PK)
USOTC
CNNA
Cann American (CE)
NYSE
IONQ
IonQ
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads